Barclays’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-27,000
Closed -$675K – 5383
2024
Q3
$675K Buy
+27,000
New +$658K ﹤0.01% 3592
2024
Q2
– Sell
-30,000
Closed -$592K – 5103
2024
Q1
$592K Buy
30,000
+8,000
+36% +$156K ﹤0.01% 3482
2023
Q4
$386K Buy
+22,000
New +$362K ﹤0.01% 4034

Other funds holding KNSA

Barclays's KNSA Position: Q3 2026 in Review

Barclays increased its Kiniksa Pharmaceuticals (KNSA) stake by 202% in Q3 2026, buying an estimated $1.95M and bringing the position to 39,687 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2354.

Barclays first reported a position in KNSA in Q3 2018 and has held it in 33 quarters since. The position peaked at $12M in Q4 2020. 305 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Barclays held 39,687 shares of Kiniksa Pharmaceuticals worth $2.96M as of Q3 2026.
  • Barclays bought 26,525 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $1.95M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2354 holding.
  • Barclays first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 33 quarters since.
  • Barclays's Kiniksa Pharmaceuticals position peaked at $12M in Q4 2020.
  • 305 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.